Aug 6, 2025 08:00 AM EDT - Jun 30, 2026 09:00 AM EDT
In-Person
Scan to view on mobile
Event Description: This educational activity is designed to enhance clinical competency in applying internationally recognized guidelines and dermatologic classification systems within rheumatology-focused care. Participants will engage in a simulated environment to explore and apply the following:
Overview of ACR/EULAR and IMACS Guidelines
Participants will be introduced to the ACR/EULAR (American College of Rheumatology/European Alliance of Associations for Rheumatology) collaborative guidelines, which provide standardized criteria for classification, disease activity assessment, and treatment response in rheumatic diseases such as rheumatoid arthritis, dermatomyositis, and systemic lupus erythematosus.
Additionally, the session will cover the IMACS (International Myositis Assessment and Clinical Studies Group) guidelines, which focus on idiopathic inflammatory myopathies (IIM), including validated core set measures, malignancy screening protocols, and consensus-based clinical trial standards. [www.eular.org] [www.niehs.nih.gov]
Application of ACR/EULAR Guidelines in a Simulated Environment
Through case-based simulations, learners will apply ACR/EULAR classification and treatment criteria to hypothetical patient scenarios. This includes evaluating disease activity, selecting appropriate pharmacologic interventions, and assessing treatment response using standardized metrics. Emphasis will be placed on shared decision-making and treat-to-target strategies.
Application of the Fitzpatrick Skin Type Classification System in a Simulated Environment
Participants will utilize the Fitzpatrick Skin Type Classification System to assess skin phototypes based on genetic disposition, sun exposure response, and tanning habits. In simulated dermatologic and rheumatologic cases, learners will determine skin type and apply this knowledge to guide safe and effective use of phototherapy, laser treatments, and sun protection strategies, particularly in patients with autoimmune skin involvement
